EU STANDARDI KRIVIČNO-PRAVNE ZAŠTITE U DOMENU FALSIFIKOVNJA LEKOVA I MEDICINSKIH PROIZVODA I DOMAĆE MATERIJALNO KRIVIČNO ZAKONODAVSTVO

Usklađivanje pravnog sistema Srbije sa standardima Evropske Unije (2022)(str. 293-308)

AUTOR(I): Snežana Soković

E-ADRESA: 

Download FullPdf  

DOI: 10.46793/UPSSX.293S

SAŽETAK:

Poznavanje problema falsifikovanih lekova i medicinskih sredstava i razumevanje standarda postavljenih Konvencijom o falsifikovanju farmaceutskih proizvoda i sličnim kažnjivim delima koja predstavljaju pretnju javnom zdravlju značajno je i za domaće prilike, obzirom da je Srbija 2019. godine potpisala ovu Konvenciju. Analiza standarda krivično pravne intervencije u domenu sprečavanja proizvodnje i distribucije falsifikovanih lekova i medicinskih proizvoda sadržanih u Konvenciji i domaćeg (materijalnog) krivičnog zakonodavstva ukazuje da buduća implementacija Konvencije nužnom čini uvođenje posebne inkriminacije falsifikovanja lekova i medicinskih proizvoda u Krivični zakonik. U radu su prikazani najbitniji elementi inkriminacije de lege ferenda, dok je u smislu drugih normativnih intervencija otvoreno pitanje legitimiteta inkriminisanja proizvodnje i prometa substandardnih lekova kao i inkriminisanje prometa neregistrovanih lekova i medicinskih sredstava.

KLJUČNE REČI:

falsifikovani lekovi, neregistrovani lekovi i medicinska sredstva, substandardni lekovi, Medicrime konvencija, Krivični zakonik, inkriminacija

LITERATURA:

  • Attaran, A., Stopping murder by medicine: introducing the Model Law on Medicine Crime, The American Journal of Tropical medicine and hygiene, 2015; 92/6.
  • Attaran, A. et al., How to Achieve International Action on Falsified and Substandard Medicines, British Medical Journal (clinical research ed.) 2012; 345:e7381.
  • Attaran, R., A counterfeit drug treaty: great idea, wrong implementation, Lancet, 2010; 376/9751.
  • Golčorbin Kon, S., Mikov, M., Falsifikovani lekovi kao globalna pretnja zdravlju, Med Pregl, 2011, LXIV (5- 6).
  • Guerin, P. J., Singh-Phulgenda, S., Strub-Wourgaft, N., The consequence of COVID-19 on the global supply of medical products: why Indian generics matter for the world; F1000Res. 2020; (published online April 1), https://f1000research.com/articles/9-225
  • Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products, Official Journal of the European Union, L 174/74;
  • Explanatory Report to the Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health, Council of Europe Treaty Series – No. 211, p. 7;
  • Zakon o lekovima i medicinskim sredstvima, Sl. glasnik RS, br. 30/2010, 107/2012, 113/2017 – dr. zakon i 105/2017 – dr. zakon.
  • Zakon o medicinskim sredstvima, Sl. glasnik RS, br. 105/2017.
  • Zakon o sprečavanju dopinga u sportu, Sl. glasnik RS, br. 111/2014 i 47/2021.
  • Johnston A, Holt, D.W., Substandard drugs: a potential crisis for public health, Britsh Journal of Clinical Pharmacology, 2014;78(2).
  • Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health, (MediCrime Convention); Council of Europe Treaty Series – No. 211/2011.
  • Kohli, V. P., Combatting Falsification and Counterfeiting of Medicinal Products in the European Union– A Legal Analysis, Copenhagen, 2019.
  • Krivični zakonik, Sl. glasnik RS, br. 85/2005, 88/2005 – ispr., 107/2005 – ispr., 72/2009, 111/2009, 121/2012, 104/2013, 108/2014, 94/2016 i 35/2019.
  • Lazarević, I., Falsifikpvanje lekova – pretnja po javno zdravlje, Beograd, 2011.
  • Mackey, TK., Liang, B.A., Kubic, T., Counterfeit drug penetration into global legitimate medicine supplay chains: a global assessment, The American Journal of Tropical medicine and hygiene, 2015; 92/6.
  • MEDICRIME VS VOLCANO: A practical case study on how the Council of Europe Convention could improve the fight against pharmaceutical crime, (Di Giorgio, D, Russo, D. coord.) Council of Europe, 2019.
  • Mujović, Zornić, H., Regulisanje pacijentovih prava u vezi sa korišćenjem lekova,
  • Pravni život, br. 9/2002.
  • Nayyar, GML. at al., Falsified and Substandard Drugs: Stopping the Pandemic, The American Journal of Tropical medicine and hygiene, 2019; 100/5.
  • Permanand, G., EU pharmaceutical regulation: the politics of policy-making. Manchester, 2006.
  • Planojević, N., Tijanić,M., Otkrivanje lažnih lekova kao preduslov zaštite žiga. Zbornik radova: Pravne i infrastrukturne osnove za razvoj ekonomije zasnovane na znanju, Kragujevac, 2013.
  • Soković, S., Falsifikovanje lekova i medicinskih sredstava – opravdanost i karakteristike krivično-pravne reakcije, Zbornik radova: Usluge i prava korisnika, Kragujevac, 2020.
  • The European regulatory system for medicines, A consistent approach to medicines regulation across the European Union;EMA/716925/2016, 2017.
  • Hall, A., Koenraadt, R., Antonopoulos, G. A., Illicit pharmaceutical networks in Europe: organisingtheillicitmedicinemarketintheUnitedKingdomandtheNetherlands, Trends in Organized Crime, 2017/20.
  • Hamilton,W.L. et al., Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies, Health Policy and Planning, 31/10, 2016.
  • WHO Global Surveillance and Monitoring System for Substandard and Falsified medical product, World Health Organization, Geneva, 2017.
  • WHO. Appendix 3, WHO Member State Mechanism on substandard/ spurious/ falsely labelled/counterfeit (SSFFC) medical products working definitions. WHO. Geneva, 2012.
  • UNICRI, Counterfeit Medicines and Organised Crime, 2012. https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/211/signatureshttps://www.coe.int/en/web/medicrime/signatures-/-ratifications,